NEW YORK, NY--(Marketwired - May 1, 2015) - Kadmon Corporation, LLC, today announced the launch of Kadmon Gene Therapy Holdings, Limited (KGT), a new, independently managed subsidiary focused on the development of novel gene therapy treatments for a range of inherited and acquired disorders.
KGT has assembled a deep pipeline of products for unmet medical needs. The company will initially focus on developing therapies for ocular diseases, including rare inherited blindness, and xerostomia following radiation treatment for head and neck cancer. KGT anticipates having four gene therapy products in clinical studies in 2016.
Importantly, KGT will retain the innovative gene regulation platform developed at Kadmon. KGT uses riboswitch technology to activate or silence expression of transgenes, achieving unprecedented levels of regulation several hundred fold greater than previously published. KGT’s gene regulation platform provides the potential to expand the way that gene therapy can be applied and creates a new paradigm for biologic therapeutics in the biopharmaceutical industry.
“KGT is developing an extensive pipeline of gene therapies treating both rare inherited diseases as well as more common acquired conditions,” said Alexandria Forbes, Ph.D., President and CEO of KGT. “The company is based on a strong foundation of innovative fundamental research, and our unique gene regulation technology puts us at the forefront of this exciting new area.”
“Gene therapy represents the future of medicine, with the potential to cure a variety of diseases at their most basic level -- the gene,” said Harlan W. Waksal, M.D., President and CEO of Kadmon. “By transferring Kadmon’s gene therapy and gene regulation research into a separate, highly focused entity, we can rapidly develop these assets and realize the intrinsic value of our gene therapy programs.”
About Kadmon Corporation
Kadmon Corporation, LLC, is a vertically integrated biopharmaceutical company focused on developing innovative products for significant unmet medical needs. We have a diversified product pipeline in autoimmune and fibrotic diseases, oncology, monogenic diseases and metabolic disease. For more information, visit www.kadmon.com.
This press release contains forward-looking statements. These forward-looking statements are based on management’s expectations and are subject to certain factors, risks and uncertainties that may cause actual results, outcome of events, timing and performance to differ materially from those expressed or implied by such statements. The information contained in this press release is believed to be current as of the date of original issue. Kadmon expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.
- gene therapy
